Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Nanostructured lipid carriers enhances the safety profile of tretinoin: in vitro and healthy human volunteers' studies

Full text
Lima, Flavia A. [1] ; Vilela, Raquel V. R. [2, 3, 4] ; Orefice, Rodrigo L. [5] ; Silva, Izabela R. [1] ; Reis, Eduardo C. O. [1] ; Carvalho, Larissa A. C. [6] ; Maria-Engler, Silvya S. [6] ; Ferreira, Lucas A. M. [1] ; Goulart, Gisele A. C. [1]
Total Authors: 9
[1] Univ Fed Minas Gerais, Dept Pharmaceut, Fac Pharm, BR-31270901 Belo Horizonte, MG - Brazil
[2] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 - USA
[3] Univ Fed Minas Gerais, Fac Pharm, Dept Clin & Toxicol Anal, BR-31270901 Belo Horizonte, MG - Brazil
[4] Michigan State Univ, Biomed Lab Diagnost, E Lansing, MI 48824 - USA
[5] Univ Fed Minas Gerais, Sch Engn, Dept Met & Mat Engn, BR-31270901 Belo Horizonte, MG - Brazil
[6] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05508000 Sao Paulo, SP - Brazil
Total Affiliations: 6
Document type: Journal article
Source: Nanomedicine; v. 16, n. 16, p. 1391-1409, APR 2021.
Web of Science Citations: 0

Aim: To enhance the tretinoin (TRE) safety profile through the encapsulation in nanostructured lipid carriers (NLC). Materials \& methods: NLC-TRE was developed using a 2(3) experimental factorial design, characterized (HPLC, dynamic light scattering, differential scanning calorimetry, x-ray diffraction analysis, transmission electron microscopy, cryo-transmission electron microscopy) and evaluated by in vitro studies and in healthy volunteers. Results: The NLC-TRE presented spherical structures, average particle size of 130 nm, zeta potential of 24 mV and encapsulation efficiency of 98%. The NLC-TRE protected TRE against oxidation (p < 0.0001) and promoted epidermal targeting (p < 0.0001) compared with the marketed product, both 0.05% TRE. The in vitro assay on reconstructed human epidermis and the measurement of transepidermal water loss in healthy volunteers demonstrated an enhanced safety profile in comparison to the marketed product (p < 0.0002). Conclusion: The NLC-TRE enhances the epidermal targeting and safety profile of TRE, representing a potential safer alternative for the topical treatment of skin disorders using TRE. (AU)

FAPESP's process: 17/04926-6 - Melanoma and chemoresistance: in vitro and in silico models to exploit therapeutic targets
Grantee:Silvya Stuchi Maria-Engler
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 18/14936-1 - Mitochondrial metabolism dictates the heterogeneity and resistance of melanoma
Grantee:Larissa Anastacio da Costa Carvalho
Support Opportunities: Scholarships in Brazil - Post-Doctorate